Carl Zeiss Meditec AG (FRA:AFX)
Germany · Delayed Price · Currency is EUR 27.10
-0.08 (-0.29%)
At close: Feb 20, 2026
Carl Zeiss Meditec AG Income Statement
Financials in millions EUR. Fiscal year is October - September.
Millions EUR. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Revenue | 2,204 | 2,228 | 2,066 | 2,089 | 1,903 | 1,647 |
Revenue Growth (YoY) | 5.89% | 7.82% | -1.11% | 9.80% | 15.55% | 23.31% |
Cost of Revenue | 1,054 | 1,052 | 977.5 | 883.54 | 775.24 | 679.57 |
Gross Profit | 1,150 | 1,175 | 1,089 | 1,206 | 1,128 | 967.21 |
Selling, General & Admin | 629.84 | 626.54 | 568.33 | 503.12 | 438.55 | 364.77 |
Research & Development | 324.28 | 326.28 | 343.09 | 349.28 | 291.37 | 232.07 |
Other Operating Expenses | 1.18 | -0.92 | - | 4.31 | - | - |
Operating Expenses | 955.3 | 951.9 | 911.42 | 856.71 | 729.92 | 596.83 |
Operating Income | 195 | 223.3 | 177.21 | 349.06 | 397.68 | 370.38 |
Interest Expense | -25.7 | -26.6 | -29.42 | -15.25 | -9.1 | -8.58 |
Interest & Investment Income | 6.07 | 6.57 | 22.4 | 28.11 | 13.25 | 1.56 |
Earnings From Equity Investments | 0.63 | 0.03 | -3.02 | -0.89 | - | - |
Currency Exchange Gain (Loss) | -8.56 | -10.46 | 11.58 | 38.2 | -48.63 | -25.1 |
Other Non Operating Income (Expenses) | -3.82 | -3.62 | 0.21 | -1.85 | -2.16 | 0.09 |
EBT Excluding Unusual Items | 163.61 | 189.21 | 178.95 | 397.38 | 351.04 | 338.35 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.1 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 2.45 |
Legal Settlements | - | - | 18.12 | - | - | - |
Other Unusual Items | 4.68 | 4.68 | 43.8 | 15.19 | 52.45 | -1.84 |
Pretax Income | 168.29 | 193.89 | 240.87 | 412.56 | 403.49 | 339.05 |
Income Tax Expense | 46.55 | 51.55 | 60.71 | 120.56 | 107.58 | 101.53 |
Earnings From Continuing Operations | 121.75 | 142.35 | 180.15 | 292.01 | 295.91 | 237.52 |
Minority Interest in Earnings | -1.14 | -1.14 | -1.43 | -1.61 | -2 | -1.24 |
Net Income | 120.61 | 141.21 | 178.73 | 290.4 | 293.91 | 236.28 |
Net Income to Common | 120.61 | 141.21 | 178.73 | 290.4 | 293.91 | 236.28 |
Net Income Growth | -23.19% | -20.99% | -38.45% | -1.20% | 24.39% | 93.06% |
Shares Outstanding (Basic) | 86 | 88 | 89 | 89 | 89 | 89 |
Shares Outstanding (Diluted) | 86 | 88 | 89 | 89 | 89 | 89 |
Shares Change (YoY) | -2.54% | -1.48% | -0.66% | - | - | - |
EPS (Basic) | 1.40 | 1.61 | 2.01 | 3.25 | 3.29 | 2.64 |
EPS (Diluted) | 1.40 | 1.61 | 2.01 | 3.25 | 3.29 | 2.64 |
EPS Growth | -21.19% | -19.80% | -38.05% | -1.20% | 24.39% | 93.06% |
Free Cash Flow | - | 170.46 | 160.51 | 185.21 | 145.4 | 332.54 |
Free Cash Flow Per Share | - | 1.95 | 1.81 | 2.07 | 1.63 | 3.72 |
Dividend Per Share | 0.550 | 0.550 | 0.600 | 1.100 | 1.100 | 0.900 |
Dividend Growth | -8.33% | -8.33% | -45.45% | - | 22.22% | 80.00% |
Gross Margin | 52.19% | 52.75% | 52.69% | 57.71% | 59.26% | 58.73% |
Operating Margin | 8.85% | 10.02% | 8.58% | 16.71% | 20.90% | 22.49% |
Profit Margin | 5.47% | 6.34% | 8.65% | 13.90% | 15.45% | 14.35% |
Free Cash Flow Margin | - | 7.65% | 7.77% | 8.87% | 7.64% | 20.19% |
EBITDA | 248.64 | 273.74 | 214.85 | 370.71 | 418.29 | 388.94 |
EBITDA Margin | 11.28% | 12.29% | 10.40% | 17.74% | 21.98% | 23.62% |
D&A For EBITDA | 53.64 | 50.44 | 37.64 | 21.65 | 20.61 | 18.56 |
EBIT | 195 | 223.3 | 177.21 | 349.06 | 397.68 | 370.38 |
EBIT Margin | 8.85% | 10.02% | 8.58% | 16.71% | 20.90% | 22.49% |
Effective Tax Rate | 27.66% | 26.58% | 25.21% | 29.22% | 26.66% | 29.95% |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.